Dear friends
A happy New Year to you.
All of you must be wishing that 2021 will be a great year and bring an end to the current Covid-19 pandemic; like what President Trump said, "one day, it will all suddenly go away...".
However, the road ahead seems long and arduous to me with many countries still facing thousands of new cases per day and certain cities having shortage of ICU beds.
Hopefully the availability of vaccines will bring on the light at the end of the tunnel.
On a different note, the new Education Committee has just been formed and we look forward to partner with you in fulfilling one of the major purposes of the Society.
This month, I have asked the en bloc Societies to pen in their thoughts on the one-year anniversary of the pandemic so that we can learn best practices from each other.
We also look forward to hearing any new ideas you have to help take the APSR on the next lap.
Best Wishes
Philip Eng
This webinar provides a space for respiratory health professionals from around the globe to share their experiences with COVID-19. The session will be chaired by the leaders of the APSR Respiratory Infections (non-tuberculous) Assembly and you have the chance to ask questions, discuss, and hear the perspectives of the presenters from Taiwan and India.
Programme
Free registration at webinar.apsr.info/webinar-20210114.
See webinar.apsr.info for further details and updates.
An online APSR Symposium will be held at NAPCON on 28 January 2021, 14:45-16:30 Indian Standard Time (IST) GMT +5:30.
NAPCON is a 5-day joint conference for the National College of Chest Physicians (India) and the Indian Chest Society. Normally staged at the end of the year, Napcon 2020 will be held in January 2021. The APSR Symposium will include the following speakers from APSR en bloc societies. See virtualnapcon2020.com for details and registration.
The APSR Research Committee launched this scheme in 2020 for APSR Assemblies and members to initiate research projects in the Asia-Pacific region. The project team should comprise APSR assembly members from more than one country in the region and there should be at least four members in the team. The project should last at least two years. APSR funding of up to US$50,000 per year is available. (Further details at apsresp.org/research.html
There were nine applications for year 2020. The research team lead by Dr Ho Namkoong has been selected.
Congratulations to Dr Ho and team!
Principal investigator: | Dr Ho Namkoong (Japan) |
Principal team members: | Dr Rachel Thomson (Australia)
Dr Byung Woo Jhun (Republic of Korea) Dr Naoki Hasegawa (Japan) Dr Kozo Morimoto (Japan) Dr Takanori Asakura (Japan) |
Pulmonary nontuberculous mycobacteria (NTM) disease is a chronic progressive pulmonary infectious disease caused by low virulence pathogens. The number of NTM patients has been increasing globally, especially in the Asia-Pacific region. Our team has been elucidating these epidemiological findings and their clinical impact.
Despite the dramatic global increase of NTM, issues such as ineffective antimicrobial agents, difficulty in the development of novel antimicrobial drugs, and risk of emergence of drug-resistant bacteria following long-term use of antimicrobial agents persist. Therefore, new strategies are warranted for better therapeutic options. Considering that NTM are ubiquitously present in the environment and have low virulence, these findings suggest a genetic predisposition to pulmonary NTM disease. However, there are few genetic studies on pulmonary NTM disease, and no genome-wide association study (GWAS) has been published for pulmonary NTM or Mycobacterium avium complex (MAC) diseases.
The Japan and Korea teams conducted the first pulmonary MAC GWAS, including 2,064 patients and 3,063 controls, including Japanese, Korean and European populations. This study provides a basis for conducting further research with a larger sample size, and we plan to establish a global research network to identify susceptible genes for pulmonary NTM disease in the Asia-Pacific region using trans-ethnic meta-analysis of GWAS and exome sequencing of familial NTM cases. We will further perform functional validation of the identified regions to better understand the pathogenesis of pulmonary NTM disease.
A joint symposium was held on 11 December during the virtual 2020 Malaysian Thoracic Society Annual Congress (MTS).
APSR members were able to watch the symposium live online.
As an en bloc society of the APSR this MTS symposium was supported by the En Bloc Society - APSR Joint Symposium scheme. To hold a joint APSR session at your own respiratory society's annual conference, see apsresp.org/education/joint-symposium.html.
Dr Kwun Fong, past president of the APSR, reports:
Well done to Dr Rozanah Abd Rahman, Organising Chairperson, Dr Lalitha Pereirasamy, (Chairperson Adult Scientific Programme for my session) and the other MTS Congress 2020 Organisers (2020.mts.org.my/committee) for their excellent work:
Assoc Prof Dr Pang Yong Kek Dr Asiah Kassim Dr N Fafwati Faridatul Akmar Mohammad Dr Eg Kah Peng Dr Helmy Haja Mydin Dr Zamzurina Abu Bakar Dr Syazatul Syakirin Sirol Aflah Dr Fauzi Mohd Anshar Dr Jiunn Liang Tan Assoc Prof Dr Ahmad Izuanuddin Ismail Dr Narasimman Sathiamurthy Dr Rashidah Yasin Dr Hooi Lai Ngoh Dr Su Siew Choo Dr Jessie De Bruyne Dr Jessie Anne de Bruyne Dr Nurhayati Mohd Marzuki Dr Su Siew Choo |
Dr Lim Wei Juan Dr Bazli Bahar Dr Noor Aliza Md Tarekh Dr Razman Shamsudin Dr Ng Yong Siang Dr Kuan Yeh Chunn Dr Nur Laily Md Yatim Dr Izyan Saleha Ibrahim Dr Tee Koh Soon Dr Ashwin Ramachandran Ms Che Juliana Che Ab Aziz Mrs Widyawati Kasban Mrs Siti Faiza Dehan Mr Samad Alias Mr Mohd Saiful Farid Mohd Jumain Mr Nor Aizie Muhamad Ms Nazuha Radzi & Ms Saidatul Nursyida Mat Rahim of the MTS Secretariat |
I was not able to attend all the wonderful sessions but the oral presentations I was privileged to hear were very high quality and to me reflects a vibrant scientific and research community, undertaking world class research to help us all achieve lung health, in keeping with the APSR vision and mission. It was a therefore a wonderful collaboration for the first ever joint MTS-APSR joint Congress Symposium and hopefully many more to follow.
And congrats to all the presenters who worked so hard (your turn will come) and to the ones who this year were selected for awards; mts.org.my/HOME/ANNOUNCEMENTS/MTS-Congress-2020-Awards. My allocated session was incredibly informative thanks to the very high quality presentations which I enjoyed with co-judges; Professor Dr Mohammed Fauzi bin Abdul Rani and Dr Renato Cutrera.
Terima Kasih MTS for the honour of participating and learning from your first ever virtual Congress which went very well and smoothly with great preparation and rehearsal, another great success for the MTS.
A joint symposium was held on 12 December during the 2020 Annual Congress of the Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM) at the NTUH International Convention Center, Taipei under the leadership of Prof. Meng-Chih Lin MD.
APSR members were able to watch the symposium live online.
As an en bloc society of the APSR this TSPCCM symposium was supported by the En Bloc Society - APSR Joint Symposium scheme. To hold a joint APSR session at your own respiratory society's annual conference, see apsresp.org/education/joint-symposium.html.
Dr Nakanishi, President of the APSR, reports:
It was a great honour to represent the APSR at the 2020 Annual Congress of the Taiwan Society of Pulmonary and Critical Care Medicine, and the Taiwan Society of Thoracic Surgeons, Taiwan Association of Thoracic & Cardiovascular Surgery Joint Conference, which was held on 12th and 13th December 2020 in Taipei, Taiwan. Because of the corona surge, the congress was held as a hybrid style; on site congress at the NTUH International Convention Center in Taipei, and online. Investigators from the USA, Australia and Japan participated in the congress over the internet. In spite of the difficult situation, the congress was very well organized and progressed smoothly.
During the congress, a TSPCCM-APSR Joint Symposium entitled "Updated management of COVID-19" was held on the first day. From the APSR, Dr Rex Chin-Wei Yung, Head of the Critical Care Medicine Assembly and I joined from the USA and Japan, respectively. And from TSPCCM, Dr Shin-Ru Shih and Prof. Kuang-Yao Yang joined on site.
We could share and learn updated information on testing, non-pharmacological and pharmacological management, and prevention of COVID-19. Since the symposium was open to members of the APSR, it would have been meaningful and worthy for not only members of the TSPCCM but also members of the APSR.
Because of the COVID-19 surge, many congresses have been postponed or forced alter their style. However, since the congress was so epoch-making and successful, I felt this congress has suggested a new direction or milestone for congresses in the future. I express sincere appreciation to all members of TSPCCM for their great efforts and kind help.
Dr Yung, Head of the APSR Critical Care Medicine Assembly, reports:
It was a privilege, honour and great pleasure that I was able to represent the APSR (Critical Care Assembly) and participate at this year's TSPCCM-APSR Joint Symposium at the 2020 Annual Congress of Taiwan Society of Pulmonary and Critical Care Medicine held on the 12 December 2020.
Because of the Covid-19 Pandemic, the focus of this year's symposia was not surprisingly on various aspects in the diagnosis and management of SARS-CoV-2, especially as it relates to prevention, diagnosis and management especially of the critically ill. Unfortunately because of the same pandemic and on-going transmission of disease, it was also a virtual meeting for the overseas presenters, including Dr Yoichi Nakanishi, the president of the APSR, and myself.
Much as the island of Taiwan has done a remarkable job in the management of this pandemic, the Local Organizing Committee of the TSPCCM is to be congratulated for their exemplary organization. This included coordinating all the preparatory work, communicating with the outside speakers, early testing of the virtual Zoom connections and presentation platforms, clarification and reminders of the disparate presentation times across different time zones, and coordinating a live (in Taiwan) audience with local presenters and remote presenters. At no time did our session seem disjointed.
The session itself comprised four 35-minute didactic presentations followed by 10-minute discussion / question and answer questions. After Professor Meng-Chih Lin (TSPCCM President) gave the welcome and introduction, Professor Shin-Ru Shih presented on state-of-the-art research on testing, specifically the "Detection of SARSCoV-2 infection: RTPCR vs. antigen rapid test vs. serologic antibody test". Then alternating with APSR speakers, Dr Rex Yung spoke on the "Non-pharmacological management of severe COVID-19 infection in ICU", highlighting the American experience but incorporating world data. Professor Kuang-Yao Yang of the TSPCCM then summarized in great detail the latest data for best evidence based "Pharmacological treatment for COVID-19: what we learn from clinical trial reports" in this rapidly moving field. Capping off the symposia was Professor Yoichi Nakanishi who brought us back to the most important aspect of management; that is prevention, with his lecture on "The effect of face covering and social distancing in preventing the transmission of COVID-19". All in all, these four presentations covered important aspects of this new worldwide pandemic. The moderators for the four talks were very effective in eliciting some questions or posed questions and learning points for the live audience and those who signed in remotely.
It is a shame that colleagues not on the island were unable to more fully enjoy the entire experience of the 2-day programme with many stimulating scientific presentations, and informal interactions. We certainly look forward to the worldwide control of the Covid-19 pandemic and return to the stage when we can all participate in person. But a combination with virtual attendees will likely also broaden the opportunity for participation by many interested parties and will foster on-going close relationships between the APSR and its many sister organizations.
Humbly submitted by Rex C Yung, MD, 15/12/2020
Grateful thanks to the following members who have strengthened the educational activities for APSR members:
The following members have kindly sent their donation towards the Society's goals, as outlined at apsresp.org/members/donors.php.
The APSR is profoundly grateful for their generosity.
The first COVID-19 patient in Hong Kong was a visitor from China in January 2020. Since then, Hong Kong has experienced three waves of COVID-19 with mainly imported cases, with a surge in March 2020 when lots of Hong Kong youngsters returned from overseas, whereas in July 2020 another wave came with mainly air crews and ship crews arriving in Hong Kong. We have been experiencing the fourth wave since November 2020 with both imported cases and cases without clear origins (local cases). The cumulative number of confirmed cases has reached 7,900 with 125 deaths.
Hong Kong people have been practising universal masking, hand hygiene and social distancing. Most government offices, public facilities and schools were closed. Nonetheless, it is impossible to lock down the whole city and thus there are still imported cases from overseas. A compulsory quarantine period has been practiced for all people coming into Hong Kong.
There are always rooms for improvement. Measures like whole population testing and reinforcement of quarantine period have been suggested to enhance detection of infection.
Further graphics for Hong Kong from worldometers.info (PowerPoint file) submitted by Dr Philip Eng
In February 2020, there were two related Covid-19 events in Indonesia, First, the Indonesian government evacuated 243 Indonesian nationals from Wuhan, China. Second, nine Indonesians on board the Diamond Princess tested positive for the virus and moved to treatment facilities in Japan. In both incidents they were placed under quarantine. On 2 March, the government announced the first two cases of Covid-19, and since then the number has increased to the current 617,820 confirmed cases, 18,819 confirmed deaths, and 5,000 – 6,000 active cases daily. Indonesia's cases are the highest number in Southeast Asia, ahead of the Philippines. In terms of the number of deaths, Indonesia ranks 3rd in Asia and 17th in the world. The number of deaths may be much higher that what has been reported since those who died with acute Covid-19 symptoms but had not been confirmed or tested are not included in the graphic below.
Indonesia has tested 4,308,544 people of its 269 million population; around 15,981 per million. The WHO has urged the nation to perform more tests, especially on suspected patients. Instead of implementing a nationwide lockdown, the government had approved large-scale social restrictions for some provinces and cities. This policy received much criticism and is considered as a disaster due to the still increasing number of cases. Even before the Covid-19 outbreak in Indonesia, capacity constraints in the health care sector have been an issue, like shortage of manpower and facilities, lack of protective equipment and operational funding issues.
Indonesia has made significant effort to provide Covid-19 tests for diagnosis. Nowadays, many health facilities can provide swab test or antigen rapid test. The government provides free Covid-19 tests in public health facilities and if people want to take paid test in private health facilities, the government has established the maximum price so that many people can take the test at an affordable price. Second, the government is already committed to providing free healthcare for anybody infected by Covid-19. Third, the government's commitment to provide Covid-19 vaccine.
The government could do better in three aspects which are:
Further graphics for Indonesia from worldometers.info (PowerPoint file) submitted by Dr Philip Eng
There have been three peaks of the coronavirus disease 2019 (COVID-19) epidemic in Japan. The first occurred from mid-March to late May. The Japanese government declared a state of emergency on 16 April to avoid a collapse of the health-care system. This led to a decrease in the number of newly infected patients and stabilized the health-care system. Therefore, the state of emergency declaration was lifted on May 25. The second peak started in late July. Cluster infections of COVID-19 cases associated with restaurants and entertainment venues were reported, and infections became more widespread across Japan. Although more infections were reported during the second peak compared with the first, these cases were mainly young people, resulting in fewer severe cases and a lower fatality rate. After peaking in early August, the number of patients decreased and restrictions on social activities such as attending concerts and sporting events were gradually eased. However, in November, the number of infections began to rise again, along with the number of severe cases. As of early December, Japan is in the midst of a third peak.
Because of no or limited number of patients experienced in the 2002–2004 severe acute respiratory syndrome (SARS) and the 2009 swine flu pandemic, Japan did not adopt recommendations such as increasing the polymerase chain reaction (PCR) testing capacity and expanding the number of available medical staff. Although Japan entered the COVID-19 epidemic with these handicaps, it has endured without experiencing a collapse of the health-care system because of the sustained efforts of medical institutions, health centre surveillance, and public awareness.
The first thing Japan did well was slowing the spread of the disease during the initial peak without resorting to a strict lockdown. This was the result of the high awareness of infection prevention among the population and thorough infection prevention measures. In addition to general prophylaxis such as wearing face masks, handwashing, and gargling, the public also followed recommendations to avoid the “Three Cs” (closed spaces, crowded places, and close-contact settings). The second thing Japan did well was conducting retrospective epidemiological investigations and enacting countermeasures against cluster infections. Patients with COVID-19 and their close contacts were identified early and quarantined. In Japan, epidemiological surveys conducted to identify the source of infections for many infectious diseases, such as tuberculosis, have traditionally been conducted by Japanese health centres. The third thing Japan did well was keeping the mortality rate lower than that in the West.
The first thing the Japanese government could have done better was to have struck a better balance between restrictions and economic activities; however, the epidemic has not been adequately controlled and Japan is currently in the midst of the third peak of the epidemic. The second thing the Japanese government could have done better was to have been better prepared for an epidemic involving viral infections. As mentioned above, due to no or limited number of patients experienced in the 2003 SARS and the 2009 swine flu pandemic, recommendations such as increasing the PCR testing capacity and expanding the number of available medical staff were not adopted in Japan. In the early stage of the COVID-19 epidemic in Japan, the PCR testing capacity was poor compared with other countries, and not all patients who wanted a test could be tested. As the medical situation tightened, Japan experienced a shortage of skilled doctors, medical engineers and nurses who could provide extracorporeal membrane oxygenation and other advanced medical services. Even if the number of available beds can be increased, fostering skilled human resources takes time. The final thing the Japanese government could have done better was to have sped up the digital transformation of the health-care system, for example, through the development of online medical treatment and COVID-19 tracking systems. These remain future issues for Japan.
Graphics for Japan from worldometers.info (PowerPoint file) submitted by Dr Philip Eng
In December 2019, the third novel coronavirus emerged in Wuhan, China. A previous study reported that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was closely related to bat-derived SARS-like coronaviruses. The disease, which is now called COVID-19, is spreading aggressively worldwide. As of 8 December 2020, 67,653,117 cases and 1,545,824 deaths worldwide had been confirmed by the World Health Organization (WHO). On 20 January 2020, the first COVID-19 case in Korea was detected in a visitor from Wuhan, China. Since then, 39,432 cases have been confirmed and 556 deaths reported by the Korean Centers for Disease Control and Prevention (KCDC) as of 8 December 2020. (Figures 1 and 2)1. This paper aims to evaluate what Republic of Korea did well and what the country could do better in its response to the COVID-19 pandemic.
Readiness for emerging infectious diseases
An outbreak of Middle East Respiratory Syndrome (MERS) occurred in Republic of Korea from May 2015 to December 2015. The MERS coronavirus infected a total of 186 people, 38 of whom have died, and that was the largest outbreak outside the Middle East2. With the lesson learned from the MERS outbreak, the government and hospitals have been preparing for the inevitable outbreak of emerging infectious diseases. The Korean government has supported $32.5 million to treat infectious diseases, designated 165 general hospitals and 20 tertiary hospitals as specialized regional infectious disease hospitals, and furnished them with isolation rooms and system setups3, 4.
Expansion of diagnostic tests and low-contact testing centres
Early detection and assessment of potential cases are critical to reducing the transmission rate of COVID-19. Republic of Korea focused on rapid and widespread testing, rather than locking down the entire city. With the expedited approval system for the urgent test kit use, a single-step, real-time RT-PCR test kit for SARS-CoV-2 that takes 6 hours was approved and available as early as 31 January this year5, 6. In December, more than 1,050 private and public health care facilities could perform diagnostic tests. The government covered the cost of tests meeting case criteria7.
In February, the first drive-through testing centres opened in Goyang, Gyeonggi province, at the city hall parking lot. The testing process, including registration, symptom check, swab sampling, and car disinfection, could be completed in less than 10 minutes for each potential case8. A walk-through diagnostic booth was created for pedestrians and used to maintain negative pressure within the testing area. Early detection of potential cases and the isolation of confirmed cases were effective in preventing COVID-19 transmission.
Response to the regional outbreak
The city of Daegu, Republic of Korea, had the first large outbreak of COVID-19 outside of China in February. As the COVID-19 spread rapidly in Daegu, a shortage of hospital beds, supplies, and health care workers occurred. There were 51 of the 54 available negative-pressure isolation beds within the city occupied only four days after the first confirmed case of COVID-19. By the end of March, more than 2,000 patients were waiting for hospital beds9. Health system leaders and public health officials rapidly adopted a regional risk stratification and triage system and recruited health care workers from other regions. In response to the shortage of hospital beds, health officials in Daegu created more than 400 negative-pressure rooms across the city. The city designated 10 hospitals only for COVID-19 patients and identified available beds in other nearby cities where they could transfer patients from Daegu who required hospital-level care9. Despite the enormous pressure on the health care system, Daegu successfully overcame the COVID-19 outbreak.
Rapid response to changing epidemic pattern
Despite the aforementioned efforts, Republic of Korea has been experiencing its third COVID-19 wave since the end of November in the metropolitan area (Seoul and Gyeonggi province). The nation is experiencing multiple infection cases in which the source cannot be specified, unlike in previous patterns. In the past, each time the epidemic surged in a particular region, the government tried to track and isolate as many cases as possible, and the number of transmissions fell within a couple of weeks. But this surge could be different. The winter season has arrived, and the cold and dry air conditions could be potentiating factors on the spread of SARS-CoV-210. Furthermore, as indoor activities increase due to the cold weather, the spread of SARS-CoV-2 is likely to become easier. At the beginning of the third COVID-19 wave, the level of social distancing should have been raised to prevent the COVID-19 epidemic. However, the government reacted slowly. As a result, COVID-19 infection has not decreased since the end of November.
Intensive care unit preparation for COVID-19 patients
With the rapid increase of COVID-19 patients from the end of November, the number of critical patients who require intensive care unit (ICU) admission is also increasing. Since 10 December, an average of 600 COVID-19 cases have been confirmed each day. Despite the soaring number of patients, the government reported that only eight ICU beds remained unoccupied that week in the entire metropolitan area11. After the second wave of COVID-19, healthcare officials should have better prepared for the expected surge in winter. However, rather than securing ICU beds or organizing a systemic intensive care system to reduce the number of COVID-19 patients, the government seemed to be more focused on recovering the business sector. The government should implement policies such as designating hospitals for critical COVID-19 patients or securing ICU beds in large tertiary hospitals before the healthcare system collapses.
Comprehensive and consistent anti-epidemic measures
Republic of Korea is a small, overpopulated country (51,289,308 inhabitants in 100,363 km2). Due to the development of transportation, the whole country became a half-day living area. Although millions of people move between cities every day in the metropolitan area, adjacent cities and provinces undertook different anti-epidemic policies. Inconsistent social distancing levels between other regions may bring a ‘balloon effect', since the current third wave in Republic of Korea is not happening in a specific cluster but through community transmission. Therefore, it is necessary to establish a comprehensive and consistent anti-epidemic policy, especially in the metropolitan area.
Recently, the U.S. Food and Drug Administration issued the first emergency use authorization for a Pfizer-BioNTech COVID-19 vaccine for the prevention of SARS-CoV-2 infection12. Other COVID-19 vaccines will soon be developed and someday be available in Republic of Korea. However, at least one more surge of COVID-19 could happen before the vaccine is sufficiently distributed. After overcoming this third wave, we need to be thoroughly prepared to cope with another wave rather than being satisfied with the result.
Further graphics for Republic of Korea from worldometers.info (PowerPoint file) submitted by Dr Philip Eng
On the 31 December 2019, pneumonia of unknown cause emerged in Wuhan city, Hubei Province of China. These cases were confirmed by the World Health Organization (WHO) on the 5 January 2020. The ministry of health (MOH) of Malaysia gave a prompt first press release for the 2019 Novel Coronavirus on the 6 January 2020. On 11 February 2020, WHO declared “COVID-19” as the official name for this disease.1 Thereafter, a global lockdown ensued due to the exponential increase in the transmission of COVID-19.
Overall, the pandemic has resulted in three waves of outbreak in Malaysia. The first outbreak was from travellers from China arriving through Singapore on the 25 January 2020. The nation witnessed its second wave after an international religious gathering held in the capital city of Kuala Lumpur from 27 February until early March 2020. Malaysia learned from the tragic lesson in Italy and implemented a movement control order (MCO)-partial lockdown, effective from 18 March 2020 until 9 June 2020 to help to contain the outbreak. Strict enforcement was conducted during the MCO period. Only essential services were allowed to operate under stringent operating protocols. The result of the MCO has “flattened the curve” of COVID-19 in Malaysia. The initial R-nought (R0) of 3.5 was reduced to 0.3.2 With the transition to a conditional MCO and subsequently recovery MCO, some restrictions were lifted in phases with the resumption of economic activities. However, the conditional MCO was re-implemented to some high prevalence regions during the third wave of outbreak in October. As of 10 December 2020, Malaysia recorded a cumulative 76,265 cases with 393 deaths.
The unprecedented outbreak in Wuhan, China, has resulted in high mortalities. This was due to the sudden surge in the number of cases that had overwhelmed its healthcare system. Thus, the MOH initiated planning and preparedness activities that focused on "surge capacity" as early as January 2020. The MOH ensured designated tertiary referral centres were set up in all states. These referral centres' bed capacity increased mainly by converting less utilized spaces and buildings into medical wards. Nationwide, a total of 60 temporary quarantine and low-risk treatment complexes were set up to house non high-risk cases. Data from both China and Italy have demonstrated that approximately 10% of patients with COVID-19 require intensive care unit (ICU) admission, and mortality rates for these patients can reach up to 50%.3 Thus, increasing the capacity of ICU beds and ventilators were heavily emphasized. All elective hospital admissions and procedures were postponed. Some health services were migrated to the telehealth platform to ensure the continuation of care for the patients. The existing smaller hospitals and the community health centres that served as screening centres were supported by the rapid response and assessment teams that facilitate risk assessment, testing, contact tracing, and various logistics of the outbreak.
Meanwhile, the MOH also developed rapid interim protocols for screening and testing from the pandemic's start. All nationwide laboratories were provided first-hand training as early as 13 January 2020 to ensure these laboratories' diagnostic capacities were optimized. By the end of September 2020, when Malaysia experienced the third wave, the nationwide laboratory test capacity exceeded expectations. To avoid smaller laboratories from being overwhelmed, especially in states that faced significant outbreaks, the MOH embarked on a collaboration with the Royal Malaysian Air Force and the national courier to urgently transport samples for testing at the Institute for Medical Research in Kuala Lumpur. Other remedial steps also included outsourcing testing services to private laboratories. Despite the global shortage of personal protective equipment (PPE), the MOH, with the support from various non-governmental or charity organizations, has taken adequate measures to ensure the proper supply of PPE for health care workers (HCWs).
During the pandemic, the MOH acknowledged the importance of the availability of human resources. To avoid this shortage, the MOH has made numerous efforts to recruit retired HCWs and volunteers, and some HCWs were temporarily redeployed to areas of significant outbreaks. The psychosocial well-being of HCWs was provided with top priorities. Many HCWs inevitably developed exhaustion both physically and psychologically. The Malaysian Ministry of Health initiated mental health and psychosocial support services (MHPSS). It is integrated with various non-government organizations and volunteer bodies to assist distressed HCWs.
The MOH drafted treatment protocols and released guidelines periodically tailored according to the latest available evidence. Asymptomatic patients were quarantined for monitoring. High-risk individuals were closely monitored in hospitals. Among medications explored included hydroxychloroquine (most frequently used) followed by various antiviral therapy. Lopinavir/ritonavir was used in 77% of severe cases.4 Steroids were initiated in slightly less than a quarter of severe COVID-19 patients before the Recovery trial published results. Patients with respiratory failure were provided with necessary ventilatory support. Some centres sparingly explored awake prone ventilation. Critical care units had a low threshold for intubation for patients with severe respiratory failure due to dilemmas faced, such as aerosol generation and patient self-inflicted lung injury (P-SILI) with the use of non-invasive ventilation therapy. Another reason was that early intubation could enhance the safety and protection of HCWs compare to emergency intubation. On the research front, Malaysia has also participated in the global Solidarity trial launched by WHO to help find an effective treatment for COVID-19.
Throughout the pandemic, the safety and well-being of all HCWs remained MOH's top priority. The available resources were never compromised. HCWs comprised approximately 4% of the total number of confirmed cases recorded nationwide. As of 9 September 2020, there were no HCW infected while managing confirmed cases. More than half of the total cases reported (53%) occurred due to workplace transmission among HCWs. Work-related transmission mainly occurred from the inadequate use of PPE while managing non-suspected cases.5
The MOH held daily press conferences throughout the pandemic. The public has easy access to these updates through the media and various social media platforms. Daily updates included the number of active cases, mortality rates, distribution of cases, bed occupancy and ventilator usage, and PPE sufficiency. Health advisories and updates were also delivered to all cellphone users via short message services to increase awareness among the public. A standardized electronic application was also introduced for the people. This "all in one" application incorporated multiple features such as updates on COVID-19, location check-ins, tracking services, information, and resources on COVID-19.
Malaysia has a massive 2-3 million migrant worker population and 178,540 refugees and asylum seekers reported by the United Nations High Commission for Refugees (UNHCR) in October 2020. The MOH also ensured that the welfare of these migrant workers, refugees and asylum seekers were not overlooked. Cooperation between MOH, UNHCR and other NGOs helped provide testing and treatment without additional cost.
A third wave let down Malaysia's success in controlling the outbreak at the end of September 2020. This was contributed by the public's complacency over government advisories once previous restrictions have been lifted. The MOH should collaborate with all stakeholders to draw up new measures and protocols to tie up loose ends in tackling the pandemic.
There were also clusters of infection attributed to withholding history by close contacts of disease or individuals who had returned from recent outbreak areas. For this reason, the ease of certain restrictions in particular to screening at entry points and social gatherings could be done at a much gradual pace. Contact screening could also be extended beyond close contacts of infection since the capacity of testing has increased at all laboratories.
Throughout the pandemic, recurrent clusters of infection have been reported involving migrant workers. The MOH could reach out to this group by conducting a regular awareness campaign at the workplace. More efforts are needed to address overcrowding and the lack of awareness of the pandemic among migrant workers.
Malaysia has witnessed many challenges during the global pandemic of COVID-19. The government has taken bold and prudent decisions to control the pandemic, and all these efforts have exceeded expectations. The sustainability of these efforts is crucial to continue to safeguard the general public's well-being.
Further graphics for Malaysia from worldometers.info (PowerPoint file) submitted by Dr Philip Eng
Although Mongolia controlled the spread of COVID-19 with no domestic infection by having strict border controls, the first domestic cluster of the new infection was registered on 11 November 2020 by an international land transport driver. Currently there are ten cluster outbreaks in Mongolia, of which one cluster has not been fully identified and surveillance is underway.
It is almost impossible to have home self-isolation due to the traditional lifestyle of Mongolians, as about 55 percent of Mongolia's population live in traditional Ger districts. For them, the risk appears to be more costly than hospitalization. But it is possible for most small families living in a house or apartment with separate rooms for family members.
More than 80 percent of those currently confirmed COVID-19 patients being treated are asymptomatic and mild due to high screening coverage. They are prevented from the spreading infection to close-contacts, as well as being provided with early treatment and having reduced complications.
The total number of confirmed cases of coronavirus is 953. There are 435 cases currently being treated and observed in home isolation. Fortunately, there are currently no deaths from COVID-19 in Mongolia.
Further graphics for Mongolia from worldometers.info (PowerPoint file) submitted by Dr Philip Eng
Like most countries, Singapore has had to deal decisively with the COVID-19 pandemic. As of 1 December 2020, Singapore's recorded 58,228 cases of COVID-19 (9,920 per 1 million population), whilst deaths from COVID-19 numbered at 29 (5 per 1 million population). There were 4,658,858 tests performed (793,690 tests per 1 million population)
Further graphics for Singapore from worldometers.info (PowerPoint file) submitted by Dr Philip Eng
COVID-19 is by far the biggest health challenge the world has faced in since the Spanish flu way back in 1918. As Sri Lanka watched COVID-19 unfold, there was wishful thinking on our part, with the warm weather and the eternal sunshine, and we would be spared of the wrath of COVID-19. The first case in Sri Lanka was detected on 27 February in a patient of Chinese nationality. Still we held on to our unwavering faith and optimism.
The first Sri Lankan patient was diagnosed on 11 March and two more cases were soon to follow. In view of the uncertain eventuality the government proactively closed the schools and the closure of the airports were soon to follow. Within a week, the country was in a state of lockdown with island wide curfew. At the same time the ministry of health issued a Clinical Practice Guideline on COVID-19, which introduced the concept of a COVID-19 triage area and a COVID-19 suspect ward while addressing case detection, disposition of patients, lab diagnosis, infection prevention control, management of high risk patients, and maintaining welfare of the HCWs. As time progressed, the case detection was mainly from overseas returnees. The lockdown was lifted and the country gradually returned to a "new normal". Subsequently two large clusters which emerged from a Naval base and a drug rehabilitation center were successfully contained.
As it was widely believed that there was no community transmission and the public lulled into a false sense of security. The schools re-opened. The general election was held. The public moved from the "new" normal back to the "old "normal and the travelling and socializing resumed.
On 4 October a COVID-19 patient from a garment factory was detected as a result of the surveillance mechanism set up by a respiratory physician. The contact tracing from this led to the garment factory and fish market clusters and the number of cases rose exponentially to a staggering 33,478. The death rate increased with 154 deaths at the time of writing. The draconian social restrictions were reinstated which included closure of schools, universities and the lockdown of high risk areas. Although the situation is somewhat controlled, the daily cases are still on the rise. This is where we are at present.
During the early stage of the pandemic, the Sri Lankan government established a National Task Force for COVID-19, comprising all major stakeholders. The task force coordinated with the defence authorities including the state intelligence services for contact tracing and mobilization of resources. More than 50 quarantine centres were established to accommodate large numbers of inbound arrivals of repatriated Sri Lankans. These were designed and successfully managed by the defence personnel. This provided the much needed assistance to the health care system to accommodate the rising numbers. The mandatory quarantine period of 14 days was strictly adhered to, to prevent the disease reaching the community.
All the positive PCR cases, regardless of the symptoms, were admitted to state sector establishments. This further prevented the disease spread in the country. The operational cell, COVID-19 triage areas and isolation units were established in each hospital and new treatment centres identified by utilizing the available local resources to accommodate those with symptoms.
Although these measures ranked Sri Lanka amongst the top countries to have successfully controlled COVID-19, there were shortcomings which probably led to the current predicament. The two-phase strategy of the "hammer and dance" which Sri Lanka adopted could have been better managed. An effective and a robust screening programme targeting the high risk population during the period of dance /"new normal" following the lockdown would have prevented the emergence of clusters. Although COVID-19 PCR was done continuously, the number of tests per day was insufficient and the screening populations were not correctly identified. There was clearly a lapse in vigilance. The golden hour that was presented to us during the period of "hammer"/lock down when the number cases were low, was not used to its maximum. This period could have been more effectively utilized to strengthen the infrastructure, equipment, manpower, expertise, training, and establishing systems in hospitals, in order to be better prepared to face the challenge once the numbers rise. Although the media played a significant role in creating public awareness about the disease and its preventive measures, it also had a negative impact on the public by stigmatizing patients and their families. This led to a reduction in health-care seeking behaviour of patients, thereby leading to reduced case detection and increased number of deaths occurring at home. The better governance of the media for a positive impact on psychological and spiritual wellbeing of people would minimize the above shortcoming. COVID-19 has brought the mighty mankind down to its knees. The lessons learnt from this pandemic will see us through, in the years to come. Vigilance, perseverance and unity is the way to victory.
Further graphics for Sri Lanka from worldometers.info (PowerPoint file) submitted by Dr Philip Eng
COVID-19 pandemic in Taiwan; what we have done and what we can do more
Since the first case of coronavirus disease 2019 (COVID-19) reported on 21 January in Taiwan (1), there have been 686 confirmed cases in Taiwan (as of 3 December). Among these patients, we have 7 deaths and 572 recoveries. As shown in Figure 1A, we can see two peaks of daily reported COVID-19 cases. The first peak occurred in March 2020 with maximum daily reported number of 27 cases. Most of these cases were imported cases of Taiwan citizens who returned from overseas (2). After April, the COVID-19 pandemic was under good control with daily reported cases below 10. The second peak has occurred since late November. Unlike the first peak, most of the reported cases in the second peak were foreign workers from Southeast Asian countries, rather than domestic people in Taiwan. As shown in Figure 1B, there are 7 reported deaths of COVID-19 cases in Taiwan, and there have been no more death cases after May 2020.
Based on the experiences learned from SARS in 2003, Taiwan is very vigilant about new outbreaks (3, 4). Our medical care systems are well-prepared for upcoming pandemics (5). Since the first occurrence of COVID-19 at the end of December 2019 in Wuhan, China, our government issued several important regulations to prevent spread of COVID-19 from oversea countries (4). Our citizens are also alert to the highly contagious characteristics of SARS-CoV2 and have high adherence to face mask and travel ban to keep social distances. Our strategies against COVID-19 are successful. The daily reported new cases of COVID-19 are maintained at low level and the mortality rate of COVID-19 patient in Taiwan is only 1%. There is no community transmission of COVID-19 in Taiwan till now and our people can keep their regular daily activities as it was before COVID-19 pandemics. The schools are open and children maintain the regular learning progress. Our profession baseball games are not shut down and the stadiums are open to the public. Taiwan takes these credits because of the effective responses from our government and cooperation from the people in Taiwan.
Some of the effective responses against COVID-19 pandemics in Taiwan are worth noting. The National Health Command Center (NHCC) was set up immediately after COVID-19 outbreak in Wuhan, China, was confirmed in late January 2020. The daily press conference provided real time and accurate information to the community and had swift reaction to the pandemics. A series of border control regulations were issued by NHCC to impose entry ban on foreign visitors. NHCC also organized the industrial resources to maximize the production of personal protective equipment (PPE), face masks and rubbing alcohol to meet the domestic demand. They also used big data analytics to make sure the epidemic prevention materials and medical supplies, especially face masks, are evenly and effectively allocated to hospitals and the public (6, 7). In addition, vigorous contact tracing to assess COVID-19 transmission dynamics were carried out in each domestic reported COVID-19 case (8). The public is well-informed about the occurrence of COVID-19 pandemics and have good awareness of the importance to keep social distance. Our people have high adherence to wear face masks when taking public transportation and when staying in indoor spaces. The behaviour of our people is the key to keep Taiwan a country free of community transmission during COVID-19 pandemics. Finally, our medical care system is well-prepared for the upcoming outbreak after the SARS pandemics in 2003 (5). We have continuing medical education activities about infectious disease annually to keep our medical staff familiar with the epidemic preventive measures (9). Many hospitals have quick responses against outbreaks, even before the COVID-19 pandemics was announced by WHO (10). The negative pressure facilities are activated early to take care of confirmed COVID-19 cases. Strict measures are implemented inside hospital to prevent the occurrence of nosocomial transmission. We have sufficient inventory of epidemic preventive materials for medical personnel. So far, there is no report of COVID-19 cases in health care workers that results from taking care of COVID-19 patients (11).
Given the success in combating COVID-19 in Taiwan, we can actually do more. The medical resources in Taiwan are abundant and we can contribute more to the development of novel medication against COVID-19. Taiwan has good experience in performing medical studies and is willing to take part in clinical trials of anti-viral agents or vaccines against COVID-19. Meanwhile, our experiences in controlling COVID-19 are valuable to other countries that are suffering from COVID-19 pandemics. Crucial policies, including border control, community transmission prevention, bailout measures, and nosocomial infection control, are proven to be effective and valid in Taiwan. The world-wide spreading of COVID-19 has shown that SARS-CoV2 knows no borders. Taiwan cannot be a place free of COVID-19 unless COVID-19 is under good control in other areas. To jointly overcome the challenges from COVID-19, Taiwan can help and Taiwan is helping.
This article was submitted to the APSR Bulletin on behalf of the Taiwan Society of Pulmonary and Critical Care Medicine.
Further graphics for Taiwan from worldometers.info (PowerPoint file) submitted by Dr Philip Eng
20 December 2020
The Forum of International Respiratory Societies (FIRS), an organisation comprised of the world's leading international respiratory societies, calls for urgent access to affordable COVID-19 vaccines globally.
The COVID-19 pandemic has affected more than 72 million people worldwide and resulted in more than 1.6 million deaths to date. No country has been spared, and throughout the world this pandemic has placed a huge burden on health systems and on economies. Many countries are now experiencing a second wave of infections, which are more severe than the first initial wave. The elderly and those with underlying vulnerabilities including diabetes, chronic lung or heart disease, hypertension, obesity or immunosuppression are at higher risk for developing severe disease.
Incredibly, less than a year after the start of the pandemic, effective, safe vaccines are now being approved for emergency use and some countries have already started vaccinating their citizens. The rapid development and authorisation of these vaccines must be accompanied by close monitoring for further guidance and optimal use. However, roll out of vaccines is currently predominantly in high-income countries. There is an urgent need for affordable vaccines to be made available in low- and middle-income countries, especially as there may be limited access to health care and to life saving supportive therapy including oxygen in these settings.
"Now is a critical time in the fight against COVID-19. We need to ensure affordable, equitable access, transparency and fair distribution of approved vaccines to protect people in all countries." said Stephanie Levine, MD President of FIRS. "This pandemic has affected people around the world and we now need a global effort to ensure that all countries can access preventive, diagnostic and therapeutic measures to beat it."
Letters from the Asia-Pacific region and beyond |
The Teaching Library is open for your self-study. Challenging yourself to choose the correct procedure for any of the cases in the Library at apsresp.org/education/teaching-library/index.php.
Many more cases are needed for this Library and any member is welcome to submit a case (or cases!) through the same link as above.
The following article has recently been selected from Respirology for its specific educational value. Previous articles on further topics can be seen at apsresp.org/education/articles/index.html
Of special interest to those working in:
* Interstitial Lung Disease
* Clinical Respiratory Medicine
Comment by Dr Mark Lavercombe:
This authors describe the functions of a multidisciplinary ILD clinic at a tertiary referral centre, expanding on the accepted role in multidisciplinary diagnosis to provide ongoing access to specialist physicians, nurses and physiotherapists in one setting. The patient perspective is provided by the use of instructive quotes from patient survey responses.
Congratulations to the following members who have recently become Fellows of the APSR:
FAPSR is a special supplementary status for any APSR member, whether they have individual or en bloc membership.
The FAPSR is a distinction available exclusively to current APSR members who meet certain requirements.
These include having more than five years of experience in healthcare or research in respiratory medicine or related disciplines.
There is a one-time joining fee, thereafter the Fellow will be entitled to use the "FAPSR" post-nominal for as long as they remain an APSR member.
Details are shown on the application page. If you have any questions about FAPSR, please contact the Secretariat APSRinfo@theapsr.org
A warm welcome to the following members who have recently joined or re-joined APSR assemblies.
Michael Agustin | Clinical Respiratory Medicine COPD Lung Cancer |
Nanang Budi Pramono | Clinical Respiratory Medicine Lung Cancer Critical Care Medicine |
Takumi Chinen | Critical Care Medicine |
Ranganath Ganga | Clinical Respiratory Medicine Lung Cancer Interstitial Lung Disease |
Sajinadiyasa I Gede Ketut | Clinical Respiratory Medicine Lung Cancer Bronchoscopy and Interventional Techniques |
Ruwanthi Jayasekera | Clinical Respiratory Medicine Respiratory Neurobiology and Sleep Tuberculosis |
Srithar Karuppasamy | Clinical Respiratory Medicine Asthma Tuberculosis |
Roshan Kumar | Bronchoscopy and Interventional Techniques Clinical Respiratory Medicine Critical Care Medicine |
Arun Sampath | Clinical Respiratory Medicine Asthma Interstitial Lung Disease |
Yoshizumi Takemura | Lung Cancer Bronchoscopy and Interventional Techniques Clinical Respiratory Medicine |
Dian Prastiti Utami | Clinical Respiratory Medicine Tuberculosis Respiratory Infections (non-tuberculous) |
Duminda Yasaratne | Asthma Clinical Allergy & Immunology Environmental & Occupational Health and Epidemiology |
See the main respiratory events in Asia-Pacific region for the next few months.
You can see the extended list on the APSR Calendar.
Articles, news or any other materials of interest to APSR members should be sent to the Bulletin Coordinator: Prof. Philip Eng drphilipeng@singnet.com.sg.